AIDOT Co., Ltd., an AI-based medical solutions company (CEO Jaehoon Jung), announced that it has significantly improved the accuracy of morphological vascular pattern analysis in the cervix with the latest technical upgrade to its cervical cancer screening system, “Cerviray AI.” Cerviray AI is an advanced medical device that analyzes lesions using AI on colposcopic (magnified cervix) images, offering a simpler and faster screening method compared to conventional cytology or HPV tests. This update introduces algorithms capable of more precisely analyzing vascular patterns, lesion texture, shape, and location within the cervix. The new model is based on a highly segmented interpretation model that meets World Health Organization (WHO) standards, boosting the identification capability of atypical vessels and high-grade lesions. AIDOT CEO Jaehoon Jung stated, “The new Cerviray AI effectively filters out elements that hinder image interpretation, such as blood and mucus, and comprehensively analyzes each patient’s unique vascular patterns, greatly improving diagnostic sensitivity and specificity. This allows for accurate early diagnosis even in areas with limited medical infrastructure, contributing to cervical cancer prevention.” This technological innovation further strengthens Cerviray AI’s position in the global market, where it already draws considerable attention. AIDOT has successfully operated AI-powered early cervical cancer diagnosis programs in Mexico, Honduras, and Bolivia, expanding into the Latin American market, as well as pursuing commercialization efforts in Southeast Asian countries like Indonesia and Vietnam, and in Mongolia. Numerous publications in SCI-level journals have already demonstrated Cerviray AI’s high sensitivity and its potential for remote diagnosis. Jaehoon Jung added, “The enhanced vascular pattern analysis technology in Cerviray AI will elevate our mission to eradicate cervical cancer. We will continue using AI technology to improve women’s health worldwide.” With this technology upgrade, AIDOT aims to accelerate obtaining US FDA 510(k) Class II clearance and European CE certification procedures within 2025. 

Korea Economic TV / 2025.04.18 / Deputy Director Yang Jae-jun